Breaking News Instant updates and real-time market news.

RF

Regions Financial

$13.53

-0.09 (-0.66%)

, TAL

TAL Education

$35.81

0.37 (1.04%)

10:20
03/25/19
03/25
10:20
03/25/19
10:20

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Regions Financial (RF) upgraded to Buy from Hold at Sandler O'Neill with analyst Stephen Scouten saying he does not believe there is more than 3%-5% of potential downside to 2021 numbers if there are not a couple of Fed rate reductions in 2020. 2. TAL Education (TAL) and New Oriental Education (EDU) upgraded to Overweight from Equal Weight at Morgan Stanley. 3. First Bancorp (FBNC) and MidSouth Bancorp (MSL) upgraded to Buy from Hold at Sandler O'Neill. 4. Lexicon (LXRX) upgraded to Hold from Sell at Gabelli with analyst Kevin Kedra citing the company's announcement that the FDA had issued a complete response letter for sotagliflozin to treat type 1 diabetes, consistent with his expectations. 5. Hibbett Sports (HIBB) upgraded to Positive from Neutral at Susquehanna. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

RF

Regions Financial

$13.53

-0.09 (-0.66%)

TAL

TAL Education

$35.81

0.37 (1.04%)

EDU

New Oriental Education

$82.74

3.22 (4.05%)

FBNC

First Bancorp

$33.93

0.37 (1.10%)

MSL

MidSouth Bancorp

$10.40

0.18 (1.76%)

LXRX

Lexicon

$5.74

-0.55 (-8.74%)

HIBB

Hibbett Sports

$22.18

0.52 (2.40%)

  • 18

    Apr

  • 24

    Apr

  • 25

    Apr

RF Regions Financial
$13.53

-0.09 (-0.66%)

02/28/19
SDLR
02/28/19
DOWNGRADE
SDLR
Hold
Regions Financial downgraded to Hold after investor day at Sandler O'Neill
As previously reported, Sandler O'Neill analyst Stephen Scouten downgraded Regions Financial to Hold from Buy on slower loan growth expectations and a smaller expected buyback following the company's investor day meeting. He maintained his 2019 EPS estimate following the event but lowered his 2020 EPS view and cut his price target on the stock to $17 from $18.
03/25/19
SDLR
03/25/19
UPGRADE
SDLR
Buy
Regions Financial upgraded to Buy from Hold at Sandler O'Neill
03/12/19
BMOC
03/12/19
INITIATION
Target $17
BMOC
Outperform
Regions Financial initiated with an Outperform at BMO Capital
BMO Capital analyst Lana Chan started Regions Financial (RF) with an Outperform rating and $17 price target. The analyst left the company's recent investor day "impressed" with its three-year strategy to improve profitability through further efficiency gains and with "seemingly moderate" credit risk. This would "upshift" Regions' profitability and should improve its "historically discounted" valuation to peers, Chan tells investors in a research note. The analyst's order of preference among Outperform-rated regional banks are BB&T (BBT), Regions, and Citizens Financial (CFG).
03/25/19
SDLR
03/25/19
UPGRADE
Target $17
SDLR
Buy
Regions Financial upgraded to Buy after four-day Fed selloff at Sandler O'Neill
As previously reported, Sandler O'Neill analyst Stephen Scouten upgraded Regions Financial to Buy from Hold with the stock having declined over 16% since Tuesday's Fed commentary, which he views as overdone. Scouten does not believe there is more than 3%-5% of potential downside to 2021 numbers if there are not a couple of Fed rate reductions in 2020. He also continues to think Regions can slowly grow loans, maintain the NIM in the current range and deliver positive operating leverage in the coming years, he tells investors. He has a $17 price target on Regions shares.
TAL TAL Education
$35.81

0.37 (1.04%)

01/15/19
MACQ
01/15/19
INITIATION
Target $32
MACQ
Outperform
TAL Education coverage transferred with an Outperform at Macquarie
Macquarie analyst John Wang assumed coverage on TAL Education with an Outperform and $32 price target saying he sees a positive turnout in the online business after the successful summer promotion and the margin improvement potential after more disciplined expansion.
11/12/18
JPMS
11/12/18
NO CHANGE
Target $48
JPMS
Overweight
Chinese education sector selloff unwarranted, says JPMorgan
The results reported mid-year in the Chinese education sector have not deteriorated sufficiently to warrant the share price performance, JPMorgan analyst Leon Chik tells investors in a research note. The analyst points out that the average education company under his coverage is down 25%-30% since the end of May. He believes this may be due to greater uncertainty over the future due to a slowing economy and an increase in government regulations. New regulations provide short term challenges but help speed up market consolidation as larger operators can cope with changes better, Chik tells investors in a research note. The analyst's top after school tutorial picks are TAL Education (TAL) and New Oriental Education (EDU). He also has an Overweight rating on Bright Scholar Education (BEDU). Chik lowered his price target for TAL to $48 from $58, for New Oriental to $85 from $98 and for Bright Scholar to $15 from $20.
01/09/19
SBSH
01/09/19
UPGRADE
SBSH
Buy
TAL Education upgraded to Buy from Neutral at Citi
03/25/19
MSCO
03/25/19
UPGRADE
MSCO
Overweight
TAL Education, New Oriental Education upgraded to Overweight at Morgan Stanley
Morgan Stanley analyst Sheng Zhong upgraded TAL Education (TAL) and New Oriental Education (EDU), both to Overweight from Equal Weight, stating that he expects China's education market to grow from close to RMB6T in 2019 to over RMB10T by 2028 and he expects stricter regulations enacted in 2018 to form a normalized environment where high-quality leading players benefit from higher barriers to entry. Zhong raised his price target on TAL Education shares to $43 from $30 and raised his price target on New Oriental shares to $95 from $65.
EDU New Oriental Education
$82.74

3.22 (4.05%)

01/22/19
LYON
01/22/19
UPGRADE
Target $83.6
LYON
Buy
New Oriental Education upgraded to Buy after earnings at CLSA
As previously reported, CLSA analyst Martin Kou upgraded New Oriental Education to Buy from Outperform after the company's revenue and margin beat in Q2 and the company issued a "robust" outlook. He expects regulatory concern to start dissipating, said Kou, who raised his price target on New Oriental shares to $83.60 from $64.20.
02/11/19
JPMS
02/11/19
DOWNGRADE
Target $80
JPMS
Neutral
New Oriental Education downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Leon Chik downgraded New Oriental Education to Neutral while raising his price target for the shares to $80 from $75. The analyst cites valuation for the downgrade as he believes the stock is "approaching fair value" following the recent rally.
03/25/19
MSCO
03/25/19
UPGRADE
MSCO
Overweight
New Oriental Education upgraded to Overweight at Morgan Stanley
FBNC First Bancorp
$33.93

0.37 (1.10%)

01/24/19
FIGP
01/24/19
UPGRADE
FIGP
Outperform
First Bancorp upgraded to Outperform from Market Perform at Fig Partners
03/25/19
SDLR
03/25/19
UPGRADE
Target $39
SDLR
Buy
First Bancorp upgraded to Buy after 11% pullback at Sandler O'Neill
As previously reported, Sandler O'Neill analyst Stephen Scouten upgraded First Bancorp to Buy from Hold, stating that the bank continues to deliver strong results, which he expects to continue. The shares are down over 11% in the past week despite no real change to the outlook for the bank or its local economies, said Scouten, who sees the pullback as a buying opportunity. He has a $39 price target on First Bancorp shares.
01/14/19
BMUR
01/14/19
NO CHANGE
Target $42
BMUR
Buy
First Bancorp set-up remains favorable, says Brean Capital
Brean Capital analyst Blair Brantley said the set-up for First Bancorp remains favorable as it is well positioned to outperform peers. He cited its sticky deposit base, growth opportunities in Charlotte, Raleigh and Wilmington, and a healthy capital base providing a strategic advantage. Brantley reiterated his Buy rating and lowered his price target to $42 from $43 on First Bancorp shares.
03/25/19
SDLR
03/25/19
UPGRADE
SDLR
Buy
First Bancorp upgraded to Buy from Hold at Sandler O'Neill
MSL MidSouth Bancorp
$10.40

0.18 (1.76%)

03/25/19
SDLR
03/25/19
UPGRADE
SDLR
Buy
MidSouth Bancorp upgraded to Buy from Hold at Sandler O'Neill
03/25/19
SDLR
03/25/19
UPGRADE
SDLR
Buy
Sandler O'Neill says 'decks cleared' at MidSouth Bancorp, upgrades to Buy
As previously reported, Sandler O'Neill analyst Stephen Scouten upgraded MidSouth Bancorp to Buy from Hold, citing his view that the bank "has largely cleared the decks" at the start of 2019 following its recent 10-K filing. He thinks that the company appears positioned to stabilize and once again grow later in 2019 with classified assets on a pro forma basis down to about 17%, Scouten tells investors. He has a $13 price target on MidSouth Bancorp shares, which he notes are approaching their 52-week lows.
08/17/18
RAJA
08/17/18
UPGRADE
RAJA
Market Perform
MidSouth Bancorp upgraded to Market Perform at Raymond James
Raymond James analyst William Wallace upgraded MidSouth Bancorp to Market Perform from Underperform following the 13D filing by Jacobs Asset Management. Wallace believes Jacobs' filing and letter to the board increases the probability the bank will sell.
11/29/18
FIGP
11/29/18
DOWNGRADE
FIGP
Market Perform
MidSouth Bancorp downgraded to Market Perform from Outperform at Fig Partners
LXRX Lexicon
$5.74

-0.55 (-8.74%)

03/14/19
GABE
03/14/19
DOWNGRADE
GABE
Sell
Lexicon downgraded to Sell at Gabelli on expected FDA rejection of sotagliflozin
As previously reported, Gabelli analyst Kevin Kedra downgraded Lexicon to Sell from Hold, citing his expectation that the FDA will reject sotagliflozin in type 1 diabetes by its March 22 PDUFA date following a split AdCom vote in January. He believes the FDA is likely to require additional information regarding a risk mitigation strategy to reduce incidences of diabetic ketoacidosis in type 1 patients on sotagliflozin, which is "a manageable hurdle," but one that will likely take additional time to navigate, Kedra tells investors. He has reduced his 2020 private market value estimate for Lexicon shares to $6.00 from $6.50.
03/14/19
03/14/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Lexicon (LXRX) downgraded to Sell from Hold at Gabelli with analyst Kevin Kedra citing his expectation that the FDA will reject sotagliflozin in type 1 diabetes by its March 22 PDUFA date following a split AdCom vote in January. 2. Sun Life Financial (SLF) downgraded to Underperformer from Neutral at CIBC. 3. Yum China (YUMC) downgraded to Outperform from Buy at Daiwa with analyst Adrian Chan citing valuation but says long-term growth remains intact. 4. Line Corp. (LN) downgraded to Underperform from Neutral at Credit Suisse. 5. Nabors Industries (NBR) downgraded to Neutral from Buy at Citi with analyst Scott Gruber saying Nabors' free cash flow outlook is weighted towards the second half of 2019, with Q1 likely to be a cash burn of $40M-plus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/25/19
GABE
03/25/19
UPGRADE
GABE
Hold
Lexicon upgraded to Hold from Sell at Gabelli
Gabelli analyst Kevin Kedra upgraded Lexicon to Hold from Sell after the company announced that the FDA had issued a complete response letter for sotagliflozin to treat type 1 diabetes, consistent with his expectations. Kedra is raising his recommendation to Hold now that the negative catalyst of the CRL has past and the stock has pulled back by over 20%. Lexicon can now look towards a European launch of sotagliflozin and Phase 3 data readouts for the type 2 program in the second half of 2019, Kedra tells investors. He has 2020 private market value estimate of $6 per share for Lexicon.
03/25/19
STFL
03/25/19
NO CHANGE
Target $10
STFL
Buy
Lexicon price target lowered to $10 from $14 after CRL receipt at Stifel
Stifel analyst Stephen Willey has adjusted his model to a "substantially more-conservative scenario" for the launch of sotagliflozin for Type 1 diabetes following Lexicon's disclosure of its receipt of a Complete Response Letter, or CRL, from the FDA regarding its new drug application. He sees a lack of near-term visibility into what will be needed to satisfy the agency's concerns and now assumes a T1D commercial launch in the first half of 2021, Willey tells investors. He lowered his price target on Lexicon shares to $10 from $14 and admits that the near-term uncertainty "makes it increasingly difficult to stay positive on the stock," but Willey keeps a Buy rating as he sees multiple milestone-yielding data disclosures upcoming from the company's studies in Type 2 diabetes.
HIBB Hibbett Sports
$22.18

0.52 (2.40%)

03/14/19
BARD
03/14/19
NO CHANGE
Target $16
BARD
Neutral
Hibbett Sports Q4 comps upside likely, says Baird
Baird analyst Peter Benedict kept his Neutral rating and $16 price target on Hibbett Sports ahead of its Q4 earnings, saying indications of improved sector demand and the company's emerging omni-channel capabilities suggest that the comps in the quarter could exceed expectations. The analyst raises his SSS forecast to up 2% from down 0.7%, but warns that material gross margin pressure is likely to constrain earnings. While the stock "looks inexpensive", Benedict believes that a "credible path to stabilize EBIT dollars remains a key hurdle."
03/25/19
SUSQ
03/25/19
UPGRADE
SUSQ
Positive
Hibbett Sports upgraded to Positive from Neutral at Susquehanna
03/22/19
BARD
03/22/19
NO CHANGE
Target $23
BARD
Neutral
Hibbett Sports price target raised to $23 from $16 at Baird
Baird analyst Peter Benedict said he is incrementally positive on Hibbett Sports following the company's strong finish to the year, though he also noted that its FY19 comparable store sales view was "slightly disappointing." He believes the stock's risk/reward looks "pretty balanced" following today's post-earnings advance and he keeps a Neutral rating on Hibbett shares, though Benedict raised his price target to $23 from $16.
03/21/19
CEDG
03/21/19
DOWNGRADE
CEDG
Equal Weight
Hibbett Sports downgraded to Equal Weight from Overweight at Consumer Edge

TODAY'S FREE FLY STORIES

01:55
12/12/19
12/12
01:55
12/12/19
01:55
General news
Asian Market Update: »

Asian Market Update:…

BILL

Bill.com

$0.00

(0.00%)

23:41
12/11/19
12/11
23:41
12/11/19
23:41
Syndicate
Bill.com 9.824M share IPO priced at $22.00 »

The deal size was raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

FTSV

Forty Seven

$36.00

1.4 (4.05%)

23:39
12/11/19
12/11
23:39
12/11/19
23:39
Syndicate
Forty Seven 4.86M share Spot Secondary priced at $35.00 »

Morgan Stanley and Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

NCR

NCR Corp.

$32.60

0.16 (0.49%)

20:34
12/11/19
12/11
20:34
12/11/19
20:34
Hot Stocks
NCR enters consent decree to resolve claims related to Kalamazoo River matter »

NCR Corporation announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

CIEN

Ciena

$35.45

0.75 (2.16%)

, LOVE

Lovesac

$14.49

0.05 (0.35%)

20:25
12/11/19
12/11
20:25
12/11/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CIEN

Ciena

$35.45

0.75 (2.16%)

LOVE

Lovesac

$14.49

0.05 (0.35%)

VERU

Veru

$2.47

0.17 (7.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 17

    Dec

  • 19

    Dec

CHEF

Chefs' Warehouse

$35.51

-0.06 (-0.17%)

20:24
12/11/19
12/11
20:24
12/11/19
20:24
Initiation
Chefs' Warehouse initiated at Piper Jaffray »

Chefs' Warehouse…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

HSBC

HSBC

$37.15

0.44 (1.20%)

20:13
12/11/19
12/11
20:13
12/11/19
20:13
Upgrade
HSBC rating change at BofA/Merrill »

HSBC upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLCE

Children's Place

$54.36

-16.31 (-23.08%)

19:54
12/11/19
12/11
19:54
12/11/19
19:54
Downgrade
Children's Place rating change at Wedbush »

Children's Place…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

LVGO

Livongo Health

$27.55

1.48 (5.68%)

19:43
12/11/19
12/11
19:43
12/11/19
19:43
Syndicate
Livongo Health 2.78M share Secondary priced at $27.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CVX

Chevron

$116.22

-1.68 (-1.42%)

19:42
12/11/19
12/11
19:42
12/11/19
19:42
Periodicals
Chevron said to be close to approving Gulf of Mexico project, Bloomberg says »

Bloomberg's Kevin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$233.00

0.03 (0.01%)

19:27
12/11/19
12/11
19:27
12/11/19
19:27
Hot Stocks
RH CEO sold 500,000 common shares of company from Dec 9 through Dec 11 »

RH announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRWD

Crowdstrike

$47.74

0.18 (0.38%)

19:17
12/11/19
12/11
19:17
12/11/19
19:17
Hot Stocks
Crowdstrike CFO sells 215K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 09

    Dec

GLD

SPDR Gold Shares

$138.94

0.98 (0.71%)

19:00
12/11/19
12/11
19:00
12/11/19
19:00
Hot Stocks
SPDR Gold Shares holdings rise to 886.22MT from 885.93MT »

This is the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$147.70

1.58 (1.08%)

, GOOG

Alphabet

$1,345.14

0.64 (0.05%)

18:59
12/11/19
12/11
18:59
12/11/19
18:59
Periodicals
Disney Plus was Google's most searched term in U.S. this year, TechCrunch says »

In the United States in…

DIS

Disney

$147.70

1.58 (1.08%)

GOOG

Alphabet

$1,345.14

0.64 (0.05%)

GOOGL

Alphabet Class A

$1,344.65

1.61 (0.12%)

AAPL

Apple

$270.71

2.09 (0.78%)

T

AT&T

$38.17

0.1 (0.26%)

NFLX

Netflix

$299.25

6.04 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 29

    Jan

DLHC

DLH Holdings

$4.58

0.525 (12.96%)

, FORM

FormFactor

$23.77

0.57 (2.46%)

18:57
12/11/19
12/11
18:57
12/11/19
18:57
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: DLH…

DLHC

DLH Holdings

$4.58

0.525 (12.96%)

FORM

FormFactor

$23.77

0.57 (2.46%)

LULU

Lululemon

$233.31

3.75 (1.63%)

NX

Quanex

$19.72

0.68 (3.57%)

TLRD

Tailored Brands

$4.85

-0.42 (-7.97%)

NDSN

Nordson

$167.44

1.69 (1.02%)

MESA

Mesa Air

$9.25

0.17 (1.87%)

OXM

Oxford Industries

$74.07

-1.89 (-2.49%)

AKTS

Akoustis

$7.60

0.11 (1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 18

    Dec

TTD

Trade Desk

$250.44

0.13 (0.05%)

18:57
12/11/19
12/11
18:57
12/11/19
18:57
Hot Stocks
Trade Desk CEO: We don't own any media »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RACE

Ferrari

$165.20

0.37 (0.22%)

18:45
12/11/19
12/11
18:45
12/11/19
18:45
Hot Stocks
Ferrari enters into new EUR 350M credit facility »

Ferrari announces that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIBT

RiceBran

$2.09

-0.105 (-4.79%)

18:43
12/11/19
12/11
18:43
12/11/19
18:43
Syndicate
RiceBran offers to sell common stock, no amount given »

Lake Street Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMW

VMware

$151.00

2.27 (1.53%)

, TSLA

Tesla

$352.40

3.58 (1.03%)

18:42
12/11/19
12/11
18:42
12/11/19
18:42
Hot Stocks
VMware's Poonen: Our networking business is on fire »

In an interview on…

VMW

VMware

$151.00

2.27 (1.53%)

TSLA

Tesla

$352.40

3.58 (1.03%)

DELL

Dell Technologies

$47.73

0.37 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 07

    Jan

  • 08

    Jan

  • 09

    Jan

  • 27

    Feb

SMTC

Semtech

$47.36

0.48 (1.02%)

18:38
12/11/19
12/11
18:38
12/11/19
18:38
Hot Stocks
Semtech director sells 19.3K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

CS

Credit Suisse

$12.95

-0.115 (-0.88%)

18:29
12/11/19
12/11
18:29
12/11/19
18:29
Periodicals
Former Credit Suisse JV exec claims she was put under surveillance, WSJ says »

Colleen Graham, a former…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

PANW

Palo Alto Networks

$226.76

1.71 (0.76%)

18:22
12/11/19
12/11
18:22
12/11/19
18:22
Hot Stocks
Palo Alto Networks CEO: No systematic problem with our sales »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

PBYI

Puma Biotechnology

$8.71

0.24 (2.83%)

18:08
12/11/19
12/11
18:08
12/11/19
18:08
Hot Stocks
Puma Biotechnology presents Phase II results of neratinib in breast cancer »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GTHX

G1 Therapeutics

$23.06

-0.18 (-0.77%)

18:05
12/11/19
12/11
18:05
12/11/19
18:05
Hot Stocks
G1 Therapeutics presents data from Phase 1b/2a trial of lerociclib at SABCS »

G1 Therapeutics reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NH

NantHealth

$0.86

-0.0225 (-2.54%)

18:01
12/11/19
12/11
18:01
12/11/19
18:01
Hot Stocks
NantHealth presents new breast cancer research findings at SABCS »

NantHealth announced new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.